S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]

  title={S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]},
  author={Wadie I. Najm and Sibylle Reinsch and Fred K. Hoehler and Jerome S. Tobis and Phillip W Harvey},
  journal={BMC Musculoskeletal Disorders},
  pages={6 - 6}
BackgroundS-Adenosylmethionine (SAMe) is a dietary supplement used in the management of osteoarthritis (OA) symptoms. Studies evaluating SAMe in the management of OA have been limited to Non Steroidal Anti-inflammatory Drugs (NSAIDs) for comparison. The present study compares the effectiveness of SAMe to a cyclooxygenase-2 (COX-2) inhibitor (celecoxib) for pain control, functional improvement and to decrease side effects in people with osteoarthritis of the knee.MethodsA randomized double-blind… 
AB0848 Symptom Modifying Effect of S-Adenosil L-Methionin in Patients with Diabetes-Associated Knee Osteoarthritis: Open Randomized Cross-Over Study
In patients with knee OA and T2DM the treatment with SAMe is associated with decreased pain, improved knee function and symptoms but has no effect on proinflammatory factors production and blood glucose level.
Efficacy and Tolerability of Advanced Glycation End-Products Inhibitor in Osteoarthritis: A Randomized, Double-Blind, Placebo-controlled Study
This study shows the efficacy of an AGE inhibitor on decreasing pain and inflammation, and increasing daily activity and mobility in OA patients.
Exploring the Mechanisms behind S-Adenosylmethionine (SAMe) in the Treatment of Osteoarthritis
Many potential mechanisms of action are examined including: reduction of inflammatory mediators; increasing levels of glutathione; direct or indirect signaling of cartilage synthesis or survival; maintenance of DNA methylation.
S-Adenosylmethionine for osteoarthritis of the knee or hip.
The effects of SAMe on both pain and function may be potentially clinically relevant and, although effects are expected to be small, deserve further clinical evaluation in adequately sized randomised, parallel-group trials in patients with knee or hip osteoarthritis.
S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review
The existing trials of SAMe, used as monotherapy or add on to another antidepressants, have shown encouraging and generally positive results, but more evidence is necessary before definitive conclusions can be drawn.
Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study
In subjects with knee pain, GCQID supplementation was effective for relieving knee pain and improving locomotor functions.
Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review.
The present review found consistent evidence that capsaicin gel and S-adenosyl methionine were effective in the management of OA, and there was some consistency to the evidence that Indian Frankincense, methylsulphonylmethane and rose hip may be effective.
Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: a systematic review.
There was no consistent evidence available for any of the reviewed substances to suggest that they were efficacious as complementary medicines to standard treatment, and the available evidence does not support their current use in the management of RA.


Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis.
OBJECTIVE We assessed the efficacy of S-adenosylmethionine (SAMe), a dietary supplement now available in the Unites States, compared with that of placebo or nonsteroidal anti-inflammatory drugs
A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis.
SAM may be an effective treatment for some patients with symptomatic knee OA, and merits further study, and intravenous loading before oral maintenance therapy may be advantageous.
Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis.
[Pharmacological and clinical aspects of S-adenosylmethionine (SAMe) in primary degenerative arthropathy (osteoarthrosis)].
An open trial, carried out on 90 patients with severe degenerative arthropathies has shown that 30 mg SAMe intravenously twice a day for 14 days have a marked anti-inflammatory effect a rather term and no side-effects.
Double-blind comparative clinical trial with S-adenosylmethionine and indomethacin in the treatment of osteoarthritis.
  • G. Vetter
  • Medicine, Psychology
    The American journal of medicine
  • 1987
Pain management in osteoarthritis: the role of COX-2 inhibitors.
  • N. Lane
  • Medicine
    The Journal of rheumatology. Supplement
  • 1997
Short term studies in dental pain, OA, and rheumatoid arthritis found that the COX-2 inhibitor celecoxib was an effective analgesic but did not cause gastroduodenal erosions, and has the potential to provide analgesia and antiinflammatory action in patients with arthritis without the side effects of NSAID.
Epidemiology of NSAID induced gastrointestinal complications.
Whether GI side effects such as dyspepsia can serve as warning symptoms for life-threatening GI complications and describes the risk factors for these events are described.
Effect of S-adenosylmethionine on experimental osteoarthritis in rabbits.
S-Adenosyl-L-methionine (SAMe): from the bench to the bedside--molecular basis of a pleiotrophic molecule.
  • T. Bottiglieri
  • Biology, Chemistry
    The American journal of clinical nutrition
  • 2002
An overview of the biochemical, molecular, and therapeutic effects of SAMe is provided, including those on depression, dementia, vacuolar myelopathy, liver disease, and osteoarthritis.